Evidence map›Paper›PMID 34011294›Full record

ArticleBMC cancer2021

Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.

Ulrich Jarry, Mégane Bostoën, Raphaël Pineau, Laura Chaillot, Valentine Mennessier, Pierre Montagne, Emilie Motte, Marjorie Gournay, Arnaud Le Goff, Thierry Guillaudeux and 1 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ulrich JarryUniversité Rennes 1, UMS 3480 CNRS/US018 INSERM BIOSIT, Laboratoire Commun ONCOTRIAL, Rennes, France. ulrich.jarry@univ-rennes1.fr.
Mégane BostoënUniversité Rennes 1, UMS 3480 CNRS/US018 INSERM BIOSIT, Laboratoire Commun ONCOTRIAL, Rennes, France.
Raphaël PineauINSERM U1242 COSS, Université Rennes 1, Clcc Eugène Marquis, Rennes, France.
Laura ChaillotINSERM U1242 COSS, Université Rennes 1, Clcc Eugène Marquis, Rennes, France.
Valentine MennessierBiotrial Pharmacology, Unité De Pharmacologie Préclinique, Rennes, France.
Pierre MontagneBiotrial Pharmacology, Unité De Pharmacologie Préclinique, Rennes, France.
Emilie MotteBiotrial Pharmacology, Unité De Pharmacologie Préclinique, Rennes, France.
Marjorie GournayINSERM U1242 COSS, Université Rennes 1, Clcc Eugène Marquis, Rennes, France.
Arnaud Le GoffBiotrial Pharmacology, Unité De Pharmacologie Préclinique, Rennes, France.
Thierry Guillaudeux *Université Rennes 1, UMS 3480 CNRS/US018 INSERM BIOSIT, Laboratoire Commun ONCOTRIAL, Rennes, France.
Rémy Pedeux *INSERM U1242 COSS, Université Rennes 1, Clcc Eugène Marquis, Rennes, France. remy.pedeux@univ-rennes1.fr.
Inserm · FRStructure Fédérative de Recherche en Biologie et Santé de Rennes · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34011294
PMCPMC8136162
OpenAlexW3163422103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.